teleo-codex/domains/ai-alignment/human-superorganism-comprises-37-trillion-eukaryotic-cells-with-300-trillion-bacterial-cells.md
Teleo Agents b6185ceb9d theseus: extract claims from 2022-00-00-americanscientist-superorganism-revolution.md
- Source: inbox/archive/2022-00-00-americanscientist-superorganism-revolution.md
- Domain: ai-alignment
- Extracted by: headless extraction cron

Pentagon-Agent: Theseus <HEADLESS>
2026-03-10 16:33:56 +00:00

1.8 KiB

type domain description confidence source created
claim ai-alignment Each human is an assemblage of 37 trillion eukaryotic cells combined with 300 trillion bacterial cells, with 2 million bacterial genes supplementing 20,000 human protein-coding genes proven American Scientist - The Superorganism Revolution (Robert Dorit, 2014) 2026-03-10

Human superorganism comprises 37 trillion eukaryotic cells with 300 trillion bacterial cells

Dorit presents the quantitative composition of the human superorganism: "Each person is, on average, an assemblage of 37 trillion eukaryotic cells combined with 300 trillion bacterial cells; the 20,000 protein-coding genes in the eukaryotic genome supplemented by 2 million bacterial genes."

This represents a fundamental inversion of genetic dominance: "Most of the genetic information inside you is not really 'you': The collective microbial genome in our gut may include 100-fold more genetic information than what can be found in our own eukaryotic cells."

The lower gut alone may house more than 30,000 different bacterial strains—exceeding the diversity of tropical rainforests (estimated at 15,000 species per acre of undisturbed habitat). This establishes humans as composite entities where the majority of genetic information and metabolic capability is microbial, not eukaryotic.

This challenges traditional notions of biological identity and the boundaries that define individual organisms. By any quantitative measure—cell count, genetic information, metabolic function—humans are superorganisms, not monolithic entities.


Relevant Notes:

Topics: